Menu
Neuromodulation is a rapidly evolving field. New approaches and technologies to treat illnesses of the mind, brain, and nervous system are continually emerging.
We understand that it can be difficult for busy clinicians to keep up with the literature in this field. We founded Pulse to make new and clinically relevant developments in the field of neuromodulation accessible to you and your practice.
Each edition of Pulse highlights key articles on TMS and other neuromodulation techniques, as well as emerging devices and technologies that offer new hope to those suffering with behavioral health and nervous system disorders.
This free monthly newsletter is brought to you by the Neuromodulation Division at UCLA. To ensure that you receive this monthly newsletter, please subscribe using the form below:
|
Pulse – July 2024 In this issue: Magnetic Seizure Therapy for depression found to be as effective as ECT, with fewer side effects. Ketamine found to be noninferior to ECT for treatment-resistant depression. Combined tDCS and virtual reality reduces PTSD symptoms. Electrical stimulation aided by use of machine learning classifiers may improve memory recall in patients with traumatic brain injury.
|
|
Pulse – June 2024 In this issue: Baseline levels of Glutamate, Glutamine, and N-acetyl aspartate may predict the outcomes of repetitive transcranial magnetic stimulation in patients with major depressive disorder
|
|
Pulse – May 2024 In this issue: Precuneus rTMS Shown Effective for Multiple Symptom Domains of Alzheimer’s Disease | Effect of Sex on Negative Symptoms of Schizophrenia After rTMS Treatment | Combined tDCS and Virtual Reality Reduces PTSD Symptoms
|
|
Pulse – April 2024 In this issue: Focal tDCS of Auditory Cortex a Potential Treatment for Chronic Tinnitus | YouTube Videos on ECT as Supportive Information for Patients | rTMS as an Effective Treatment for Psychomotor Slowing in Psychosis | Transcranial Pulse Stimulation as a Promising Treatment for Neuropsychiatric Symptoms in Alzheimer’s Disease
|
|
Pulse – March 2024 In this issue: Potential Benefits of rTMS for Cannabis Use Disorder (CUD) | Prefrontal Short-Term rTMS No Different from Sham in Treating Alzheimer’s Disease (AD) | Vagus Nerve Stimulation (VNS) for Depression May Reduce the Number of Psychiatric Hospitalizations and Subsequent Neuromodulatory Treatments | Vagus Nerve Stimulation Observed as Effective for Narcolepsy Management
|
|
Pulse – February 2023 In this issue: Different Symptom Rating Scales Confer Varying Abilities to Detect rTMS Treatment Response in TRD
|
|
Pulse – January 2023 In this issue: Magnetic Seizure Therapy for Depression Found to Be as Effective as ECT, with Fewer Side Effects
|
|
Pulse – December 2023 In this issue: The Impact of ECT on a common causal circuit in depression
|
|
Pulse – November 2023 In this issue: Electrical Stimulation Aided by Use of Machine Learning Classifiers May Improve Memory Recall in Patients with Traumatic Brain Injury
|
|
Pulse – October 2023 In this issue: Long-Term Gray Matter Volume Decreases Associated with Electroconvulsive Therapy for Major Depressive Disorder | Cognitive Impairment in Late Onset Depression Improved with rTMS | Accelerated Protocols with Broad-Coil rTMS with H1 Demonstrate Effectiveness for TRD | Evidence of Imaging Markers of Pain-Autonomic Coupling in Complex Regional Pain Syndrome and Alleviation with rTMS of the Somatosensory Cortex
|
|
Pulse – September 2023 In this issue: Pretreatment Pupillary Reactivity is Associated with rTMS Treatment Outcome for MDD | Twice Daily Inpatient rTMS for Depression Associated with Shorter Hospitalization Duration than Once Daily Treatment | DepressionDC: tDCS Appears Ineffective as Augmentation Treatment for Major Depressive Disorder | A Greater Number of Unsuccessful Treatments is Associated with Diminished Outcomes in rTMS for Late Life Depression
|
|
Pulse – August 2023 In this issue: tDCS Found Not to Augment Cognitive Training in Randomized Clinical Trial | Transcranial Direct Current Stimulation (tDCS) May Reduce Relapse Risk in Alcohol Use Disorder Through Functional Connectivity Changes | High-frequency rTMS May Improve Poststroke Dysphagia after Infratentorial Stroke | Multimodal Magnetic Resonance Imaging Biomarker May Predict ECT Outcomes for Depression
|
|
Pulse – July 2023 In this issue: Ketamine Found to be Noninferior to ECT for Treatment-Resistant Depression | Accelerated rTMS Found to Act Faster than Intranasal Esketamine in Treatment-Resistant Depression | ECT Is More Effective than rTMS for Treating Psychotic Depression and Equivalent for Non-Psychotic Depression | Ketamine as Anesthesia in ECT for Depression May Accelerate Response
|
|
Pulse – June 2023 In this issue: Meta analysis Suggests tACS Improves Cognition Across Populations | Systematic Review Confirms Safety Profile of rTMS | Spatiotemporal Biomarker of TRD Found to Normalize with Successful Accelerated iTBS | Twice Daily rTMS is Safe and Effective for TRD
|
|
Pulse – April 2023 In this issue: Functional Connectivity Mapping Between DLPFC TMS Target and sgACC Has Only a Weak Correlation with Treatment Outcome | Theta-Alpha Amplitude Modulation Frequency Is a Biomarker for Prolonged Intermittent Theta Burst Stimulation Efficacy in Treatment-Resistant Depression | cTBS to Bilateral Temporoparietal Cortex May Be Effective at Reducing Severity of Auditory Verbal Hallucinations | tACS Improves Working and Long-Term Memory in Healthy Older Adults with Spatiotemporal Specificity
|
|
Pulse – March 2023 In this issue: Cardiovascular Biomarkers May Predict Response to Accelerated Low Frequency rTMS in MDD | rTMS May Be a Safe and Effective Treatment for Children and Adolescents with MDD | Meta-Analysis Finds DBS to be Effective in Treatment Resistant OCD | Responsive DBS to Bilateral Nucleus Accumbens Improved Loss-of-control Eating in Two Patients with Refractory Binge Eating Disorder
|
|
Pulse – February 2023 In this issue: rTMS May be More Effective in OCD Patients with Lower Levels of SSRI Resistance | High-frequency rTMS to the Precuneus May Preserve Cognitive Function in Mild-Moderate Alzheimer’s Disease | Successful Treatment of TRD with ECT is Mediated by Improvements in Negative Cognitive Schemas | Factors Associated with Response to ECT for Mania Identified in Registry Study
|
|
Pulse – January 2023 In this issue: Adjunctive D-Cycloserine May Enhance iTBS Outcomes in Patients with MDD | High-Frequency rTMS Improves Depression and Insomnia More than Sham when Combined with Agomelatine | Electroconvulsive Therapy May Be a Viable Treatment for Obsessive-Compulsive Disorder | Borderline Personality Disorder Associated with Increased Risk of Relapse of Depression in Patients Treated with Electroconvulsive Therapy
|
|
Pulse – December 2022 In this issue: Neurostructural Frontolimbic Changes after rTMS Treatment in Adolescents with TRD | tDCS Accelerated Fear Extinction and Safety Learning in Adults with OCD ECT for Late-Life | Depression: Long-Term Outcomes May Be Comparable to Other Treatments | Meta-Analysis Suggests High-Frequency rTMS May Be an Effective Treatment for PTSD
|
|
Pulse – November 2022 In this issue: Combination of rTMS and CBT Shows Promise for Relapse Reduction in Alcohol Dependency | Sham Stimulation Outperforms “Deep” TMS with an H7 Coil when Combined with Brief Exposure Therapy in the Treatment of PTSD | HFL-rTMS May Have Efficacy Comparable to ECT in MDD and Reduce Cognitive Adverse Effects | Anodal tDCS to Left DLPFC Shows Promise in Enhancing Inhibitory Control in Individuals with Obesity
|
|
Pulse – October 2022 In this issue: Bilateral TBS is Noninferior to Standard Sequential Bilateral rTMS for Major Depression | Home-based tDCS Yields Positive Results for Adults with Osteoarthritis | ECT More Efficacious than Ketamine for TRD in Recent Small-Scale Meta-Analysis
|
|
Pulse – September 2022 In this issue: Superior Temporal Gyrus Functional Connectivity Predicts Response to tDCS for Auditory Hallucinations in Schizophrenia | Excitatory Non-Invasive Stimulation of Left DLPFC Shows Promise for Treating Negative Symptoms in Patients with Schizophrenia | Low-Frequency rTMS Improves Auditory Hallucinations in Schizophrenia and Normalizes Aberrant Measures of Nucleus Accumbens Functional Connectivity | HFL rTMS Yields Modest Benefits for Positive Symptoms in Long-Term-Hospitalized Veterans with Schizophrenia
|
|
Pulse – August 2022 In this issue: Bilateral Cerebellum rTMS Improves Cognition in Patients with Alzheimer’s | Improved Response Inhibition Correlates with EEG Biomarkers after Successful HFL rTMS for Depression | tDCS May Be a Nonpharmacological Treatment Alternative for Inattention in Adults With ADHD | Transcutaneous Auricular Vagus Nerve Stimulation Yields Benefits Similar to Citalopram in a Randomized Trial for Patients with MDD
|
|
Pulse – July 2022 In this issue: Transcranial Direct Current Stimulation Failed to Separate from Sham in Patients with Depression | Quantitative EEG Guided TMS May Improve Outcomes in Depression rTMS Proves Effective for Smoking Cessation in a Pivotal Multicenter Double-Blind RCT | A Review of Evidence Supporting “Preservation TMS” to Maintain Symptom Improvement in Depression
|
|
Pulse – June 2022 In this issue: Inpatient ECT is Associated with a Significantly Reduced Risk of Suicide for Patients with Severe Depression | rTMS Appears Safe and Effective for Pregnant Women with Major Depressive Disorder | Dorsomedial Prefrontal rTMS is Effective for Depression in Women with Borderline Personality Disorder | Meta-analysis of Noninvasive Brain Stimulation for Anxiety Disorders Shows Promising Results
|
|
Pulse – May 2022 In this issue: Scrambler Therapy Especially Effective for a “Paroxysmal” Subset of Neuropathic Pain | A Review of Potential Transdiagnostic Benefits with rTMS to DLPFC in MDD and AUD | Theta Burst Stimulation of the Orbitofrontal Cortex May Modulate Compulsive | A Single Sub-threshold HFrTMS Session May Modulate Testosterone Levels Behavior
|
|
Pulse – April 2022 In this issue: Retrospective analysis of patients treated with a standard course of rTMS for MDD, patients taking psychostimulants showed a significantly greater decrease in the IDS-SR30 compared to those not taking these medications.
|
|
Pulse – March 2022 In this issue: Modulation of Evoked Potentials by Initial 10 Hz rTMS Session Predicts Clinical Outcomes of a Six-Week Treatment Course | Large-Scale Structural Network Changes Correlate with Clinical Response to rTMS in Depression rTMS Shows Promise for Treatment of Tardive Syndromes | iTBS to Left DLPFC Significantly Modulates TMS- Evoked Cortical Potentials in a Dose-Independent Manner
|
|
Pulse – February 2022 In this issue: rTMS to Primary Motor Cortex Provides Superior Relief of Neuropathic Pain Intensity Compared to Prefrontal Cortex and Sham.
|
|
Pulse – January 2022 In this issue: Expert review of the FDA-approved peripheral nerve stimulator Relivion® describes a handful of blinded and unblinded studies which suggest the device provides superior efficacy in chronic migraine and may be useful in the treatment of depression.
|
|
Pulse – December 2021 In this Issue: Improvements in Depression in Patients with Schizophrenia Spectrum Disorders receiving rTMS.
|
|
Pulse – November 2021 In this Issue: rTMS is effective for the treatment of depression with comorbid anxiety disorder · Positive Outcomes in Clinical Trial of Stanford Neuromodulation Therapy (SNT) for MDD · Twice versus Once Daily rTMS Treatment Does Not Accelerate Antidepressant Response · Closed-Loop DBS Alleviates Intractable Depression in Proof-of-Concept Case Study.
|
|
Pulse – October 2021 The October 2021 issue covers a large-scale registry-based study in primarily community settings using TMS for MDD demonstrated greater antidepressant effects than earlier clinical trials, with better results in women and those who received a larger number of pulses.
|
|
Pulse – September 2021 The September 2021 issue covers the outcome of TMS treatment of major depressive disorder and comorbid chronic pain associated with neurophysiologic biomarkers, promising early data for TMS in treatment of comorbid MDD and OCD, and rTMS to dorsomedial prefrontal cortex effective for treatment of anorexia nervosa with comorbid MDD.
|
|
Pulse – August 2021 The August 2021 issue covers subthreshold priming associated with improved outcomes in rTMS for MDD, acute improvements found with rTMS for cocaine use disorder, how rTMS may be less affected by borderline personality traits than ECT and improved negative symptoms in schizophrenia with high-frequency transcranial random noise stimulation.
|
|
Pulse – July 2021 The July 2021 issue covers a naturalistic study of rTMS in bipolar depression, a clinical trial investigating iTBS in bipolar depression, the use of a personalized, fMRI-based rTMS target in treating depression, the effects of extending the course of deep TMS treatment, and the impact of concomitant bright light therapy on rTMS treatment outcomes.
|
|
Pulse – June 2021 The June 2021 issue covers emerging TMS paradigms for the treatment of depression, TMS for the treatment of depression in adolescents, the negative impact of concomitant lorazepam use on TMS outcomes, the findings of an MRS study suggesting that increases in GABA signaling at the DLPFC may correlate with TMS response, and an easy-to-use tDCS headset available without a prescription in the EU.
|
|
Pulse – May 2021 The May 2021 issue covers the efficacy of high frequency TMS with a shortened inter-train interval, TMS for the treatment of PTSD, a randomized controlled trial comparing accelerated TMS to standard TMS treatment, the durability of TMS response, and tDCS for the negative symptoms of schizophrenia.
|
|
Pulse – April 2021 This issue covers TMS for the treatment of insomnia, TMS for the treatment of depression in Parkinson’s Disease, TMS treatment of comorbid MDD and OCD, a priming protocol that enhances the efficacy of low-frequency right-sided stimulation for depression, trigeminal nerve stimulation (TNS) for ADHD in children, and a novel device that provides bimodal acoustic and electrical somatosensory stimulation for the treatment of tinnitus.
|
|
Pulse – March 2021 This issue covers an exciting accelerated TMS protocol, methods for improving TMS outcomes for early non-responders, TMS treatment of negative symptoms of schizophrenia, theta-burst stimulation for depression, the efficacy of tDCS in depression, and an app for chronic insomnia.
|